Dana‑Farber/Harvard Breast Cancer Innovation Fund
Development Research Program
This program gives seed funding to speed new tests, treatments, and early trials for people with breast cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11015470 on NIH RePORTER |
What this research studies
From a patient point of view, this program gives small, focused grants to Dana‑Farber/Harvard investigators so promising ideas for breast cancer can move faster toward the clinic. Awards are typically $50,000–$75,000 with additional support possible from partner hospitals, and funds can support lab work, use of patient samples, or early-stage clinical work. The program issues broad calls for proposals across DF/HCC member institutions and selects promising projects to receive rapid development support. Past DRP awards at DF/HCC have led to important publications, new external grants, and the launch of innovative clinical trials.
Who could benefit from this research
Good fit: Ideal participants are people with breast cancer who receive care at Dana‑Farber, Massachusetts General Hospital, Beth Israel Deaconess, or other DF/HCC member institutions and who are willing to join early clinical studies or donate samples.
Not a fit: People without breast cancer or patients who do not receive care at the DF/HCC member hospitals are unlikely to be eligible or to directly benefit from these funded projects.
Why it matters
Potential benefit: If successful, the program could speed development of new treatments and increase access to early clinical trials for breast cancer patients at participating centers.
How similar studies have performed: This seed‑funding model has a strong track record at DF/HCC, with prior DRP awards producing high‑impact papers, new grants, and new clinical trials.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Brown, Myles a — Dana-Farber Cancer Inst
- Study coordinator: Brown, Myles a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.